Oral osmotically driven systems: 30 years of development and clinical use

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 73, Issue 3, 2009, Pages 311-323

  Malaterre, Vincent ^a,b   Ogorka, Joerg ^a   Loggia, Nicoletta ^a   Gurny, Robert ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Controlled drug delivery; GITS; Life cycle management; Oral osmotic systems; OROS; Osmotic pumps; Review

Indexed keywords

ALTOPLUS XR; CARBAMAZEPINE; CARDURA CR; CARVEDILOL; CYCLOBENZAPRINE; DILTIAZEM PLUS ENALAPRIL MALEATE; DITROPAN UB; DITROPAN UD; DOXAZOSIN; FLEXERIL XL; GLIPIZIDE PLUS METFORMIN; INDOMETACIN; LIDOCAINE; LORAZEPAM; MELATONIN; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METHYLPHENIDATE; METOPROLOL; MEVINOLIN; NIFEDIPINE; NITRENDIPINE; OSMORAN 300; OXPRENOLOL; OXYBUTYNIN; PALIPERIDONE; PHENYLPROPANOLAMINE; POLYMER; PREDNISOLONE; PSEUDOEPHEDRINE; RANITIDINE; SALBUTAMOL SULFATE; TEGRETOL XL; TENIDAP; TEOSONA SOL; THEOPHYLLINE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MANUFACTURE; DRUG MARKETING; DRUG PULSE THERAPY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EQUIPMENT DESIGN; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; GASTROINTESTINAL TRANSIT; HUMAN; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE PERFORATION; INTESTINE ULCER; MAXIMUM PLASMA CONCENTRATION; MEDICAL TECHNOLOGY; METABOLIC DISORDER; NEUROLOGIC DISEASE; NONHUMAN; OSMOTIC PUMP; PATENT; PATIENT COMPLIANCE; RESPIRATORY TRACT DISEASE; REVIEW; SCHIZOPHRENIA; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; INDOMETHACIN; INFUSION PUMPS; OSMOTIC PRESSURE; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 70350393913     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.07.002     Document Type: Review

References (193)

1. Amabile C.M., and Bowman B.J. Overview of oral modified-release opioid products for the management of chronic pain. Ann. Pharmacother. 40 7-8 (2006) 1327-1335
2. Prisant L.M., and Elliott W.J. Drug delivery systems for treatment of systemic hypertension. Clin. Pharmacokinet. 42 11 (2003) 931-940
3. Michelson E.L. Calcium-antagonists in cardiology - update on sustained-release drug delivery systems. Clin. Cardiol. 14 12 (1991) 947-950
4. Conley R., Gupta S.K., and Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr. Med. Res. Opin. 22 10 (2006) 1879-1892
5. Grundy J.S., and Foster R.T. The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokinet. 30 1 (1996) 28-51
6. Bass D.M., Prevo M., and Waxman D.S. Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS (R)) - a retrospective study. Drug Saf. 25 14 (2002) 1021-1033
7. Rose S., and Nelson J.F. A continuous long-term injector. Aust. J. Exp. Biol. 33 (1955) 415
8. T. Higuchi, H. Leeper, Alza Corp. Osmotic dispenser, US Patent 3732,865, May 15, 1973.
9. F. Theeuwes, T. Higuchi, Osmotic dispensing device for releasing beneficial agent, US Patent 3845,770, May 11, 1974.
10. Theeuwes F. Elementary osmotic pump. J. Pharm. Sci. 64 12 (1975) 1987-1991
11. Verma R.K., Krishna D.M., and Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Rel. 79 1-3 (2002) 7-27
12. Theeuwes F., Swanson D., Wong P., Bonsen P., Place V., Heimlich K., and Kwan K.C. Elementary osmotic pump for indomethacin. J. Pharm. Sci. 72 3 (1983) 253-258
13. Weintraub M., Ginsberg G., Stein E.C., Sundaresan P.R., Schuster B., O'Connor P., and Byrne L.M. Phenylpropanolamine OROS (Acutrim) vs. placebo in combination with caloric restriction and physician-managed behavior modification. Clin. Pharmacol. Ther. 39 5 (1986) 501-509
14. Heilmann K. Gits - a new medicine administration system. Zeit. Rheum. 41 4 (1982) 137
15. Bertouch J.V., Maycock S., Harrington B., and Brooks P.M. Pharmacokinetics of indomethacin gits (osmotically controlled delivery system). Aust. NZ. J. Med. 13 2 (1983) 212
16. Francis H., Corrigan A.B., Hill W., Geddes R., and Brooks P. The gastro intestinal therapeutic systems (gits) for indomethacin to decrease side-effects. Aust. NZ. J. Med. 13 2 (1983) 212
17. Calin A. Intestinal perforation associated with osmotic slow release indomethacin capsules. Br. Med. J. 288 6412 (1984) 240-241
18. Donnelly P. Indomethacin and perforated duodenal ulcer. Br. Med. J. 281 6234 (1980) 230
19. Laidler P., Maslin S.C., and Gilhome R.W. What's new in osmosin and intestinal perforation?. Pathol. Res. Pract. 180 1 (1985) 74-76
20. Brodie D.A., Cook P.G., Bauer B.J., and Dagle G.E. Indomethacin-induced intestinal lesions in the rat. Toxicol. Appl. Pharmacol. 17 3 (1970) 615-624
21. Coutrot S., Roland D., Barbier J., Van Der M.P., Alcalay M., and Matuchansky C. Acute perforation of colonic diverticula associated with short-term indomethacin. Lancet 2 8098 (1978) 1055-1056
22. Naciazek-Wieniawska A., and Krus S. Studies on the cumulation of the toxic effect of indomethacin. Pol. Med. Sci. Hist. Bull. 15 1 (1975) 35-39
23. Shack M.E. Drug induced ulceration and perforation of the small intestine. Ariz. Med. 23 7 (1966) 517-523
24. Weintraub M., Horn J.H., Krakoff L., and Vetrovec G. P+T committee review of nifedipine gits - new modality for angina and hypertension. Hosp. Form. 25 (1990) 10-14
25. Elliott H.L., and Meredith P.A. Nifedipine gits. Lancet 341 8840 (1993) 306
26. Ruilope L.M. Long-term protection in at-risk hypertensive patients - a role for nifedipine GITS?. Blood Press 11 2 (2002) 106-109
27. Prisant L.M., Carr A.A., Bottini P.B., and Kaesemeyer W.H. nifedipine gits (gastrointestinal therapeutic system) bezoar. Arch. Int. Med. 151 9 (1991) 1868-1869
28. Kwon H.Y., Scott R.L., and Mulloy J.P. Small bowel procardia XL tablet bezoar mimicking cystic pneumatosis intestinalis. Abdom. Imag. 21 2 (1996) 142-144
29. Coghill D., and Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin. Pharmacother. 7 15 (2006) 2119-2138
30. Santus G., and Baker R.W. Osmotic drug-delivery - a review of the patent literature. J. Control. Rel. 35 1 (1995) 1-21
31. Kaushal A.M., and Garg S. An update on osmotic drug delivery patents. Pharm. Tech. 27 1 (2003) 38-44
32. Kumar P., and Mishra B. An overview of recent patents on oral osmotic drug delivery systems. Recent Patent Drug Del. Form. 1 3 (2007) 236-255
33. Verma R.K., Mishra B., and Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 26 7 (2000) 695-708
34. Verma R.K., Arora S., and Garg S. Osmotic pumps in drug delivery. Crit Rev. Ther. Drug Carrier Syst. 21 6 (2004) 477-520
35. Meredith P.A. The unique adalat story - nifedipine gastrointestinal therapeutic system. Eur. Cardiovasc. Dis. 1 1 (2007) 97-102
36. Theeuwes F. Evolution and design of 'rate controlled' osmotic forms. Curr. Med. Res. Opin. 8 S2 (1983) 20-27
37. Gupta S.K., and Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol. 39 1 (1999) 289-296
38. Sun J.X., Niecestro R., Phillips G., Shen J., Lukacsko P., and Friedhoff L. Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans. J. Clin. Pharmacol. 42 2 (2002) 198-204
39. P. Holm, T. Norling, Lifecycle Pharma. Pharmaceutical compostion comprising lercanidipine, W.O. Patent 2005/053689. December 1, 2004.
40. Corrigan O.I. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. Adv. Exp. Med. Biol. 423 (1997) 111-128
41. Amidon G.E., He X., and Hageman M.J. In: Abraham D.J. (Ed). Burgers Medicinal Chemistry and Drug Discovery vol. 2 (2004), Wiley-Interscience, New York (Chapter 18)
42. Yu L.X. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res. 25 4 (2008) 781-791
43. Modi N.B., Lam A., Lindemulder E., Wang B., and Gupta S.K. Application of in vitro-in vivo correlations (IVIVC) in setting formulation release specifications. Biopharm. Drug Dispos. 21 8 (2000) 321-326
44. Okimoto K., Miyake M., Ohnishi N., Rajewski R.A., Stella V.J., Irie T., and Uekama K. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug, using (SBE) (7m)-beta-CD. Pharm. Res. 15 10 (1998) 1562-1568
45. Langenbucher F., and Mysicka J. In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations. Br. J. Clin. Pharmacol. 19 S2 (1985) 151S-162S
46. Grundy J.S., Grace D.W., and Foster R.T. Observation of time-dependent and variable subject kinetics in a nifedipine gastrointestinal therapeutic system bioequivalency study. J. Control. Rel. 44 2-3 (1997) 247-254
47. Shah J., Langmuir V., and Gupta S.K. Feasibility and functionality of OROS melatonin in healthy subjects. J. Clin. Pharmacol. 39 6 (1999) 606-612
48. Wang C., Chen F., Li J.Z., Tang H., Li X., Yan K.S., Ye G.H., and Pan W.S. A novel osmotic pump tablet using core of drug-resin complexes for time-controlled delivery system. J. Pharm. Soc. Jpn. 128 5 (2008) 773-782
49. Thombre A.G. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Disc. Today 10 17 (2005) 1159-1166
50. C.M. Chen, Andrx Pharmaceuticals, Controlled release formulation having a preformed passageways, W.O. Patent 9640080, December 19, 1996.
51. C. M. Chen, J. Chou, D. Wong, Andrx Pharmaceuticals, HMG-CoA reductase inhibitor extended release formulation, W.O. Patent 0134123, May 17, 2001.
52. X.X. Cheng, C.M. Chen, S. Jan, J. Chou, Andrx Pharmaceuticals, Method for treating diabetes via administration of controlled release metformin, US Patent 6790,459, September 14, 2004.
53. G.M. Zentner, K.J. Himmelstein, G.S. Rork, Merck & Co., Multiparticulate controlled porosity osmotic, US Patent 4851,228, July 25, 1989.
54. P.S. Wong, F. Theeuwes, A. Ayer, A.L. Kuczynski, Alza Corp., Dosage form for time-varying pattern of drug delivery, W.O. Patent 9204011, March 19, 1992.
55. Theeuwes F., Swanson D.R., Guittard G., Ayer A., and Khanna S. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br. J. Clin. Pharmacol. 19 S2 (1985) 69S-76S
56. Zentner G.M., Rork G.S., and Himmelstein K.J. The controlled porosity osmotic pump. J. Control. Rel. 1 4 (2002) 269-282
57. Liu L., and Wang X. Solubility-modulated monolithic osmotic pump tablet for atenolol delivery. Eur. J. Pharm. Biopharm. 68 2 (2008) 298-302
58. Prabakaran D., Singh P., Kanaujia P., and Vyas S.P. Effect of hydrophilic polymers on the release of diltiazem hydrochloride from elementary osmotic pumps. Int. J. Pharm. 259 1-2 (2003) 173-179
59. Yang X.G., Zhang G.H., Li W., Peng B., Liu Z.D., and Pan W.S. Design and evaluation of jingzhiguanxin monolithic osmotic pump tablet. Chem. Pharm. Bull. 54 4 (2006) 465-469
60. R.R. Magruder, B.L. Barclay, P.S. Wong, F. Theeuwes, Alza Corp., Composition comprising a therapeutical agent and a modulating agent, US Patent 4751,071, June 14, 1988.
61. R. R. Magruder, B. L. Barclay, P. S. Wong, F. Theeuwes, Composition comprising salbutamol, U.S Patent 4751,071, June 14, 1988.
62. Okimoto K., Tokunaga Y., Ibuki R., Irie T., Uekama K., Rajewski R.A., and Stella V.J. Applicability of (SBE) (7m)-beta-CD in controlled-porosity osmotic pump tablets (OPTs). Int. J. Pharm. 286 1-2 (2004) 81-88
63. G. Myers, Fuisz Technologies Ltd., Drug delivery systems utilizing liquid crystal structures, April 6, 1999.
64. E. Rudnic, B.A. Burnside, H.H. Flanner, S.E. Wassink, R.A. Couch, J.E. Pinkett, Osmotic drug delivery system, US Patent 6110,498, August 29, 2000.
65. A. Ayer, F. Theeuwes, P.S. Wong, Alza Corp., Controlled delivery of haloperidol by an osmotic delivery system, US Patent 4610,686, September 9, 1986.
66. D. Swanson, D. Edgren, Alza Corp., Osmotic device that improves delivery properties of agents in situ, US Patent 4326,525, April 27, 1982.
67. G.M. Zentner, G.A. Mcclelland, Merck & Co., Solubility modulated drug delivery device, US Patent 4994,273, February 19, 1991.
68. Liu L., Khang G., Rhee J.M., and Lee H.B. Monolithic osmotic tablet system for nifedipine delivery. J. Control. Rel. 67 2-3 (2000) 309-322
69. Ramakrishna N., and Mishra B. Plasticizer effect and comparative evaluation of cellulose acetate and ethylcellulose-HPMC combination coatings as semipermeable membranes for oral osmotic pumps of naproxen sodium. Drug Dev. Ind. Pharm. 28 4 (2002) 403-412
70. Liu X., Chen D., and Zhang R. Evaluation of monolithic osmotic tablet system for nifedipine delivery in vitro and in vivo. Drug Dev. Ind. Pharm. 29 7 (2003) 813-819
71. Kanagale P., Lohray B.B., Mishra A., Davadra P., and Kini R. Formulation and optimization of porous osmotic pump-based controlled release system of oxybutinin. AAPS PharSciTech 8 3 (2007) E53
72. He L., Gong T., Zhao D., Zhang Z.R., and Li L. A novel controlled porosity osmotic pump system for sodium ferulate. Pharmazie 61 12 (2006) 1022-1027
73. Bindschaedler C., Gurny R., and Doelker E. Osmotic water transport through cellulose acetate membranes produced from a latex system. J. Pharm. Sci. 76 6 (1987) 455-460
74. Bindschaedler C., Gurny R., and Doelker E. Mechanically strong films produced from cellulose acetate latexes. J. Pharm. Pharmacol. 39 5 (1987) 335-338
75. Jensen J.L., Appel L.E., Clair J.H., and Zentner G.M. Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate/methacrylate copolymer latexes. J. Pharm. Sci. 84 5 (1995) 530-533
76. P.S. Wong, F. Theeuwes, Alza Corp., Aqueous emulsion for pharmaceutical dosage form, US Patent 5019,397, May 28, 1991.
77. Appel L.E., and Zentner G.M. Use of modified ethylcellulose lattices for microporous coating of osmotic tablets. Pharm. Res. 8 5 (1991) 600-604
78. Park J.S., Shin J.H., Lee D.H., Kim M.S., Rhee J.M., Lee H.B., and Khang G. A squeeze-type osmotic tablet for controlled delivery of nifedipine. J. Biomater. Sci. Polym. 19 1 (2008) 31-45
79. Rani M., Surana R., Sankar C., and Mishra B. Development and biopharmaceutical evaluation of osmotic pump tablets for controlled delivery of diclofenac sodium. Acta Pharm. 53 4 (2003) 263-273
80. Gan Y., Pan W.S., Wei M.C., and Zhang R.H. Cyclodextrin complex osmotic tablet for glipizide delivery. Drug Dev. Ind. Pharm. 28 8 (2002) 1015-1021
81. Nokhodchi A., Momin M.N., Shokri J., Shahsavari M., and Rashidi P.A. Factors affecting the release of nifedipine from a swellable elementary osmotic pump. Drug Deliv. 15 1 (2008) 43-48
82. Shokri J., Ahmadi P., Rashidi P., Shahsavari M., Rajabi-Siahboomi A., and Nokhodchi A. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 68 2 (2008) 289-297
83. Ozdemir N., and Sahin J. Design of a controlled release osmotic pump system of ibuprofen. Int. J. Pharm. 158 1 (1997) 91-97
84. F. Theeuwes, R.J. Saunder, W.S. Mefford, Alza Corp., Process for forming outlet passageways in pills using a laser, May 9, 1978.
85. Liu L.X., and Che B.J. Preparation of monolithic osmotic pump system by coating the indented core tablet. Eur. J. Pharm. Biopharm. 64 2 (2006) 180-184
86. J.G. Luschen, Alza Corp., Process for forming a passageway in an osmotic device, US Patent 4271,113, June 2, 1981.
87. G. Guittard, J. Deters, F. Theeuwes, R. Cortese, Alza Corp., Osmotic system with instant drug availability, US Patent 4576,604, March 19, 1986.
88. J. Faour, J. Mayorga, Phoenix (osmotica), Multi-layer osmotic device, W.O. Patent 1998/9853802, December 3, 1998.
89. D. Edgren, Alza Corp., Drug dispenser comprising wall formed of semipermeable member and enteric member, US Patent 4522,625, June 11, 1985.
90. Sinchaipanid N., Pongwai S., Limsuwan P., and Mitrevej A. Design of salbutamol EOP tablets from pharmacokinetics parameters. Pharm. Dev. Technol. 8 2 (2003) 135-142
91. D.N. Bhalachand, M.A. Prabakar, Oral osmotic controlled drug delivery system, US Patent 2003219485, November 27, 2003.
92. B. Schluetermann, M. Kohlmeyer, P. Vanhoogevest, H. Tiemessen, ADD Advanced Drug Development, Peroral therapeutic system comprising glipizide, W.O. Patent 2001/0191716, December 6, 2001.
93. S. Khanna, Ciba Geigy (Novartis). Therapeutic system for sparingly soluble active ingredients, US Patent 4992,278, February 12, 1991.
94. A.D. Koparkar, S.B. Shah, Oral osmotic system for slightly soluble active agents, US Patent 5284,662, December 16, 1991.
95. Zentner G.M., Mcclelland G.A., and Sutton S.C. Controlled porosity solubility-modulated and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J. Control. Rel. 16 1-2 (1991) 237-243
96. J. Faour, M.A. Ricci, Phoenix (Osmotica), Osmotic device containing pseudoephedrine and an H1 antagonist, W.O. Patent 0151038, July 19, 2001.
97. J. Faour, M.A. Coppari, Phoenix (Osmotica), Osmotic device within an osmotic device, W.O. Patent 0151036, July 19, 2001.
98. Liu H., Yang X.G., Nie S.F., Wei L.L., Zhou L.L., Liu H., Tang R., and Pan W.S. Chitosan-based controlled porosity osmotic pump for colon-specific delivery system: screening of formulation variables and in vitro investigation. Int. J. Pharm. 332 1-2 (2007) 115-124
99. P.S. Wong, F. Theeuwes, Alza Corp., Colon delivery system, September 15, 1987.
100. P. Bonsen, P.S. Wong, F. Theeuwes, Alza Corp., Method of delivering drug with aid of effervescent activity generated in environment of use, US Patent 4265,874, May 5, 1981.
101. P. Bonsen, P.S. Wong, F. Theeuwes, Alza Corp. Method of delivering drug with aid of effervescent activity generated in environment of use, US Patent 4344,929, August 17, 1982.
102. Li X.D., Pan W.S., Nie S.F., and Wu L.J. Studies on controlled release effervescent osmotic pump tablets from traditional Chinese medicine compound recipe. J. Control. Rel. 96 3 (2004) 359-367
103. F. Theeuwes, Osmotic dispenser with gas generating means, US Patent 4036,228, July 19, 1977.
104. J. L. Haslam, G. S. Rork, Merck & Co., Controlled porosity osmotic pump, US Patent 4880,631, November 14, 1989.
105. F. Theeuwes, Alza Corp. Device for dispensing by combined diffusional and osmotic operations, US Patent 4235,236, November 25, 1980.
106. Okimoto K., Ohike A., Ibuki R., Aoki O., Ohnishi N., Rajewski R.A., Stella V.J., Irie T., and Uekama K. Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)(7m)-beta-CD as both a solubilizer and osmotic agent. J. Control. Rel. 60 2-3 (1999) 311-319
107. G.A. Mcclelland, G.M. Zentner, Merck & Co., Solubility modulated drug delivery system, US Patent 4946,686, August 7, 1990.
108. Mcclelland G.A., Sutton S.C., Engle K., and Zentner G.M. The solubility-modulated osmotic pump - invitro invivo release of diltiazem hydrochloride. Pharm. Res. 8 1 (1991) 88-92
109. L.E. Appel, C.A. Brown, J.S. Burton, H. Huatan, N. Loggia, D. Supplee, Pfizer, Controlled-release dosage form, W.O. Patent 2007057762, May 24, 2007.
110. R.Cortese, F. Theeuwes, Alza Corp., Osmotic device with hydrogel driving member, US Patent 4327,725, May 4, 1982.
111. Liu L., and Xu X. Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int. J. Pharm. 352 1-2 (2008) 225-230
112. Liu L.X., Ku J., Khang G., Lee B., Rhee J.M., and Lee H.B. Nifedipine controlled delivery by sandwiched osmotic tablet system. J. Control. Rel. 68 2 (2000) 145-156
113. Malaterre V., Ogorka J., Loggia N., and Gurny R. Evaluation of the tablet core factors influencing the release kinetics and loadability of push-pull osmotic systems. Drug Dev. Ind. Pharm. 35 4 (2009) 433-439
114. Thombre A.G., Appel L.E., Chidlaw M.B., Daugherity P.D., Dumont F., Evans L.A.F., and Sutton S.C. Osmotic drug delivery using swellable-core technology. J. Control. Rel. 94 1 (2004) 75-89
115. Malaterre V., Ogorka J., Loggia N., and Gurny R. Approach to design push-pull osmotic pumps. Int. J. Pharm. 376 1-2 (2009) 56-62
116. V. Malaterre, M. Pedersen, J. Ogorka, R. Gurny, N. Loggia, P.F. Taday, Terahertz pulsed imaging, a novel process analytical tool to investigate the coating characteristics of push-pull osmotic systems, Eur. J. Pharm. Biopharm., in press, doi:10.1016/j.ejpb.2008.10.011.
117. P. S. Wong, B.L. Barclay, J.C. Deters, F. Theeuwes, Alza Corp., Osmotic device with dual thermodynamic activity, US Patent 4612,008, September 16, 1986.
118. A. Ayer, C.A. Christopher, D.R. Guinta, S.K. Gupta, L.G. Hamel, Z. Hatamkhany, A.C. Lam, S.R. Saks, P. Shivanand, R.G. Weyers, J.D. Wright, Alza Corp., Methods and devices for providing prolonged drug therapy, W.O. Patent 1999/9962496, December 9, 1999.
119. E. Cruz, S.X. Li, B.J. Pollock, G.C. Ruhlmann, C. Garcia, A.M. Wong, L.G. Hamel, Alza Corp., OROS push-stick for controlled delivery of active agents, W.O. Patent 2005/030166, April 7, 2005.
120. L.C. Dong, C. Pollock-Dove, J. Han, Alza Corp. Composition and method for enhancing bioavailability, W.O. Patent 2005/051358, May 9, 2005.
121. N.B. Modi, S.K. Gupta, N. Davar, S.M. Seroff, Alza Corp., Osmotic dosage forms for controlled delivery of alprazolam, W.O. Patent 2005/030180, April 7, 2005.
122. F. Theeuwes, G. Guittard, P.S. Wong, Alza Corp., Delivery of drug to colon by oral dosage form, US Patent 4904,474, February 27, 1990.
123. F. Jao, P.S. Wong, H.T. Huynh, K. McChesney, P.K. Wat, Alza Corp., System for delaying drug delivery up to seven hours, US Patent 6146,662, November 14, 2000.
124. B.L. Barclay, J.D. Childers, J.D. Wright, V. Place, P.S. Wong, Alza Corp., Oral osmotic device with hydrogel driving member, W.O. Patent 1990/001130, September 11, 1990.
125. B.L. Barclay, J.D. Childers, J.D. Wright, V. Place, P.S. Wong, Alza Corp., Oral osmotic device with hydrogel member, US Patent 5021,053, June 4, 1991.
126. V. Place, P.S. Wong, B.L. Barclay, J.D. Childers, Alza Corp., Oral osmotic device for delivering nicotine, U.S Patent 5147,654, September 15, 1992.
127. Encarnacion M., and Chin I. Salivary nystatin concentrations after administration of an osmotic controlled release tablet and a pastille. Eur. J. Clin. Pharmacol. 46 6 (1994) 533-535
128. C.F. Grove, P.J. Dehlinger, D.R. Friend, F.J. Martin, M. Ferrari, California University and Imedd, Particles for oral delivery of peptides and proteins, W.O. Patent 0041740, July 20, 2000.
129. J.A. Fix, L.C. Dong, C. Pollock, K.O. Shafi, P.J.M. Dor, P.S.L. Wong, CHRONSET(R) oral osmotic system capabilities and applications, Abs. Papers Am. Chem. Soc. 213 (1997) 233-MSE.
130. L.C. Dong, P.S. Wong, S.H. Yum, L.G. Hamel, M.H. Dealey, B.J. Pollock, Alza Corp., Osmotic device with delayed activation of the drug delivery and complete drug release, W.O. Patent 1996/9638130, December 5, 1996.
131. Breimer D.D., and Deboer A.G. Potential use of osmet-osmotic pumps in pharmaceutical and pharmacological research in man. Pharmaceutisch Weekblad-Scientific Edition 8 1 (1986) 101
132. Deboer A.G., Danhof M., Delange S., Weeda H.W.A., Schmidt R.J.P., and Breimer D.D. Plasma-concentration profile, and beta-blockade of oxprenolol following rate-controlled oral (oros) and rectal (osmet) administration in volunteers. Acta Pharmacologica Et Toxicologica 59 (1986) 86
133. Soons P.A., and Breimer D.D. Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male-subjects. Br. J. Clin. Pharmacol. 32 1 (1991) 11-16
134. Thombre A.G., Zentner G.M., and Himmelstein K.J. Mechanism of water transport in controlled porosity osmotic devices. J. Memb. Sci. 40 3 (1989) 279-310
135. Thombre A.G., Cardinal J.R., DeNoto A.R., and Gibbes D.C. Asymmetric membrane capsules for osmotic drug delivery II. In vitro and in vivo drug release performance. J. Control. Rel. 57 1 (1999) 65-73
136. Thombre A.G., DeNoto A.R., and Gibbes D.C. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients. J. Control. Rel. 60 2-3 (1999) 333-341
137. A.G. Thombre, Pfizer, Delivery device having encapsulated excipients, W.O. Patent 9412152, June 9, 1994.
138. P.S. Wong, F. Theeuwes, B.L. Barclay, M.H. Dealey, Alza Corp., Osmotic dosage system for liquid drug delivery, W.O. Patent 9115196, October 17, 1991.
139. L.C. Dong, K. Shafi, A. Yum, P.S. Wong, Alza Corp., Oral dosage from comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition, W.O. patent 2004/002448, January 8, 2004.
140. Malaterre V., Metz H., Ogorka J., Gurny R., Loggia N., and Mäder K. Benchtop-magnetic resonance imaging (BT-MRI) characterization of push-pull osmotic controlled release system. J. Control. Rel. 133 1 (2009) 31-36
141. J. Frank, P.S. Wong, H.T. Hynh, K. McChesney, P.K. Wat, Alza Corp., Verapamil therapy, US Patent 5160,744, November 3, 1992.
142. Connor D.F., and Steingard R.J. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 18 14 (2004) 1011-1030
143. Breimer D.D., and Deboer A.G. Potential use of osmet - osmotic pumps in pharmaceutical and pharmacological research in man. Pharmaceutisch Weekblad-Scientific Edition 8 1 (1986) 101
144. Ritschel W.A. Targeting in the gastrointestinal-tract - new approaches. Methods and Findings in Experimental and Clinical Pharmacology 13 5 (1991) 313-336
145. Deleede L.G.J., Deboer A.G., Feijen C.D., and Breimer D.D. Site specific rectal drug administration in man with an osmotic system - influence on 1st-pass elimination of lidocaine. Pharm. Res. 3 (1984) 129-134
146. Davis S.S., Hardy J.G., Taylor M.J., Whalley D.R., and Wilson C.G. The effect of food on the gastrointestinal transit of pellets and an osmotic device (osmet). Int. J. Pharm. 21 3 (1984) 331-340
147. Davis S.S., Hardy J.G., Taylor M.J., Stockwell A., Whalley D.R., and Wilson C.G. The invivo evaluation of an osmotic device (osmet) using gamma scintigraphy. J. Pharm. Pharmacol. 36 11 (1984) 740-742
148. Dong L.C., Wong P.S., Wang J., and Shafi K. L-OROS sofcap for controlled release of non-aqueous liquid formulations. Drug Deliv. Technol. 2 1 (2002) 52-55
149. P.S. Wong, S.K. Gupta, B.D. Steward, Osmotically controlled tablets, in: Drugs and the Pharmaceutical Sciences: Modified-Release Drug Delivery Technology, Marcel Dekker AG (2003), pp. 101.
150. Langman M.J., and Henry D. Indomethacin and perforated duodenal ulcer. Br. Med. J. 280 6221 (1980) 1088-1089
151. Sathyan G., Hwang S., and Gupta S.K. Effect of dosing time on the total intestinal transit time of non-disintegrating systems. Int. J. Pharm. 204 1-2 (2000) 47-51
152. Davis S.S., Washington N., Parr G.D., Short A.H., John V.A., Lloyd P., and Walker S.M. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol oros 16/260 drug delivery system within the gastrointestinal-tract as determined by scintigraphy. Br. J. Clin. Pharmacol. 26 4 (1988) 435-443
153. Wilding I.R., Davis S.S., Hardy J.G., Robertson C.S., John V.A., Powell M.L., Leal M., Lloyd P., and Walker S.M. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral-administration of carbamazepine as a controlled-release system and as a suspension of n-15-labeled drug to healthy-volunteers. Br. J. Clin. Pharmacol. 32 5 (1991) 573-579
154. John V.A., Shotton P.A., Moppert J., and Theobald W. Gastrointestinal transit of oros drug delivery systems in healthy volunteers: a short report. Br. J. Clin. Pharmacol. 19 S2 (1985) 203S-206S
155. Khosla R., Feely L.C., and Davis S.S. Gastrointestinal transit of non-disintegrating tablets in fed subjects. Int. J. Pharm. 53 2 (1989) 107-117
156. Abrahamsson B., Alpsten M., Jonsson U.E., Lundberg P.J., Sandberg A., Sundgren M., Svenheden A., and Tolli J. Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon. Int. J. Pharm. 140 2 (1996) 229-235
157. Wilson C.G., and Hardy J.G. Gastrointestinal transit of an osmotic tablet drug delivery system. J. Pharm. Pharmacol. 37 8 (1985) 573-575
158. Sood A., and Panchagnula R. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. Int. J. Pharm. 261 1-2 (2003) 27-41
159. Wonnemann M., Schug B., Schmucker K., Brendel E., van Zwieten P.A., and Blumel H. Significant food interactions observed with a nifedipine modified-release formulation marketed in the European Union. Int. J. Clin. Pharmacol. Ther. 44 1 (2006) 38-48
160. Schug B.S., Brendel E., Chantraine E., Wolf D., Martin W., Schall R., and Blume H.H. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast. Br. J. Clin. Pharmacol. 53 6 (2002) 582-588
161. Kostewicz E., Sansom L., Fishlock R., Morella A., and Kuchel T. Examination of two sustained release nifedipine preparations in humans and in pigs. Eur. J. Pharm. Sci. 4 6 (1996) 351-357
162. Schug B.S., Brendel E., Wonnemann M., Wolf D., Wargenau M., Dingler A., and Blume H.H. Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfast. Eur. J. Clin. Pharmacol. 58 2 (2002) 119-125
163. Schug B.S., Brendel E., Wolf D., Wonnemann M., Wargenau M., and Blume H.H. Formulation-dependent food effects demonstrated for nifedipine modified-release preparations marketed in the European Union. Eur. J. Pharm. Sci. 15 3 (2002) 279-285
164. Abrahamsson B., Alpsten M., Bake B., Jonsson U.E., Eriksson-Lepkowska M., and Larsson A. Drug absorption from nifedipine hydrophilic matrix extended-release (ER) tablet-comparison with an osmotic pump tablet and effect of food. J. Control. Rel. 52 3 (1998) 301-310
165. Sathyan G., Hu W.T., and Gupta S.K. Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J. Clin. Pharmacol. 41 2 (2001) 187-192
166. ® Tablets (10 mg, ALZA) in healthy volunteers: trials OXYB-02109 & OXYB-0262, Mylan Pharmaceuticals (2006).
167. Lukkari E., CastrenKortekangas P., Juhakoski A., Loyttyniemi E., Aranko K., and Neuvonen P.J. Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur. J. Clin. Pharmacol. 50 3 (1996) 221-223
168. Lukkari E., Aranko K., Juhakoski A., Hakonen T., and Neuvonen P.J. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Pharmacol. Toxicol. 81 1 (1997) 31-34
169. Chung M., Vashi V., Puente J., Sweeney M., and Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br. J. Clin. Pharmacol. 48 5 (1999) 678-687
170. Midha K.K., Mckay G., Rawson M.J., Korchinski E.D., and Hubbard J.W. Effects of food on the pharmacokinetics of methylphenidate. Pharm. Res. 18 8 (2001) 1185-1189
171. Modi N.B., Wang B., Hu W.T., and Gupta S.K. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharm. Drug Dispos. 21 1 (2000) 23-31
172. Auiler J.F., Liu K., Lynch J.M., and Gelotte C.K. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR food evaluation (CAFE) study. Curr. Med. Res. Opin. 18 5 (2002) 311-316
173. Lee L., Kepple J., Wang Y., Freestone S., Bakhtiar R., Wang Y., and Hossain M. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm. Drug Dispos. 24 6 (2003) 233-243
174. Teo S.K., Scheffler M.R., Wu A., Stirling D.I., Thomas S.D., Stypinski D., Khetani V.D., single-dose A., and crossover t.-w. bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects. J. Clin. Pharmacol. 44 2 (2004) 173-178
175. Chao S.T., Prather D., Pinson D., Coen P., Pruitt B., Knowles M., and Place V. Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system. J. Pharm. Sci. 80 5 (1991) 432-435
176. Hwang S.S., Gorsline J., Louie J., Guinta D., and Hamel L. In-vitro and in-vivo evaluation of a once-daily controlled-release pseudoephedrine product. J. Clin. Pharmacol. 35 3 (1995) 259-267
177. Sathyan G., Xu E., Thipphawong J., and Gupta S.K. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin. Pharmacol. 7 (2007) 2
178. Vashi V., Harris S., El Tahtawy A., Wu D.L., and Cipriano A. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules. J. Clin. Pharmacol. 45 5 (2005) 547-554
179. John V.A., and Smith S.E. Influence of food-intake on plasma oxprenolol concentrations following oral-administration of conventional and oros preparations. Br. J. Clin. Pharmacol. 19 (1985) S191-S195
180. Lecaillon J.B., Massias P., Schoeller J.P., and Abadie F. Influence of food on the absorption of metoprolol administered as an oros drug delivery system to man. Br. J. Clin. Pharmacol. 19 (1985) S245-S249
181. Vandenberg G., Vansteveninck F., Gubbensstibbe J.M., Schoemaker H.C., Deboer A.G., and Cohen A.F. Influence of food on the bioavailability of metoprolol from an oros system - a study in healthy-volunteers. Eur. J. Clin. Pharmacol. 39 3 (1990) 315-316
182. Melander A., Danielson K., Schersten B., and Wahlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin. Pharmacol. Ther. 22 1 (1977) 108-112
183. Rackley R.J. Examples of in vitro in vivo relationships with a diverse range of quality. In vitro-in vivo correlations 423 (1997) 1-15
184. FDA, Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms: Scale-up and Post-approval Changes: Chemistry, Manufacturing and Controls, in vitro Dissolution Testing, and in vivo Bioequivalence Documentation (1997).
185. Malinowski H., Marroum P., Uppoor V.R., Gillespie W., Ahn H.Y., Lockwood P., Henderson J., Baweja R., Hossain M., Fleischer N., Tillman L., Hussain A., Shah V., Dorantes A., Zhu R., Sun H., Kumi K., Machado S., Tammara V., OngChen T.E., Mahayni H., Lesko L., and Williams R. Draft guidance for industry extended-release solid oral dosage forms - development, evaluation and application of in vitro in vivo correlations. In Vitro-In Vivo Correlat. 423 (1997) 269-288
186. Grundy J.S., Anderson K.E., Rogers J.A., and Foster R.T. Studies on dissolution testing of the nifedipine gastrointestinal therapeutic system. 1. Description of a two-phase in vitro dissolution test. J. Control. Rel. 48 1 (1997) 1-8
187. Defang O., Shufang N., Wei L., Hong G., Hui L., and Weisan P. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev. Ind. Pharm. 31 7 (2005) 677-685
188. Pitsiu M., Sathyan G., Gupta S., and Verotta D. A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin. J. Pharm. Sci. 90 6 (2001) 702-712
189. Civiale C., Ritschel W.A., Shiu G.K., Aiache J.M., and Beyssac E. In vivo-in vitro correlation of salbutamol release from a controlled release osmotic pump delivery system. Methods Find. Exp. Clin. Pharmacol. 13 7 (1991) 491-498
190. Warrington S.J., Barclay S.P., John V.A., Shotton P.A., Wardle H.M., and Good W. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 oros administration. Br. J. Clin. Pharmacol. 19 Suppl. 2 (1985) 219S-224S
191. Godbillon J., Gerardin A., Richard J., Leroy D., and Moppert J. Osmotically controlled-delivery of metoprolol in man - invivo performance of oros systems with different durations of drug release. Br. J. Clin. Pharmacol. 19 (1985) S213-S218
192. Royce A., Li S.F., Weaver M., and Shah U. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2′-O-methyladenosine. J. Control. Rel. 97 1 (2004) 79-90
193. Wei L.L., Li J., Guo L.R., Nie S.F., Pan W.S., Sun P.N., and Liu H. Investigations of a novel self-emulsifying osmotic pump tablet containing carvedilol. Drug Dev. Ind. Pharm. 33 9 (2007) 990-998